DMAAR
Drugs Made In America Acquisition Corp.
Set alert
0.09 USD -0.02 -16.44%
0.1089 Day range 0.1089
0.091 52-week range 0.1089
- YTD
- -16.44%
- 1 year
- -16.44%
- Open
- 0.1089
- Prev close
- 0.1089
- Mkt cap
- 264.25M
- Vol
- 154
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1089
- High
- 0.1089
Financial health
Altman Z-Score
23.37 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 5
- Debt / Equity 1
- P/E 5
- P/B 1
Valuation
P/E 54.6×
FY 2024 5y median -61.6× FY 2025
P/S 0.0×
FY 2024 5y median 0.0× FY 2025
P/B 0.9×
FY 2024 5y median -174932× FY 2025
P/FCF -404×
FY 2024 5y median -144892× FY 2025
EV/EBITDA -77.4×
FY 2024 5y median 50.4× FY 2025
EV/Sales 0.0×
FY 2024 5y median 0.0× FY 2025
FCF Yield -0.2%
FY 2024 5y median -0.1% FY 2025
Profitability
Gross Margin 0.0%
FY 2024 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2024 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2024 5y median 0.0% FY 2025
ROE 2.6%
FY 2024 5y median 99.4% FY 2025
ROIC -1.2%
FY 2024 5y median -5.0% FY 2025
ROA 2.5%
FY 2024 5y median -42.2% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2024 FY 2025
Operating Income -587794.2%
FY 2024 FY 2025
EPS (diluted) 439.3%
FY 2024 FY 2025
Free Cash Flow -182675.3%
FY 2024 FY 2025
Financial Health
Current Ratio 0.0×
FY 2024 5y median 3.2× FY 2025
Quick Ratio 0.0×
FY 2024 5y median 3.2× FY 2025
Debt / Equity 0.0×
FY 2024 5y median -1.4× FY 2025
Net Debt / EBITDA 0.0×
FY 2024 5y median 0.0× FY 2025
Interest Coverage 0.0×
FY 2024 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2024 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2024 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31